Chronic Lymphocytic Leukemia Articles | Page 2

Liso-Cel Continues to Show Promise in Relapsed/Refractory CLL/SLL
The CD19-directed CAR T-cell therapy lisocabtagene maraleucel showed promising clinical activity and manageable toxicity in heavily pretreated patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma, all of whom had progressed on ibrutinib.
Zanubrutinib Effective in CLL/SLL, Regardless of Del(17p) Status
The BTK inhibitor zanubrutinib continues to demonstrate high overall response rates for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, regardless of the presence of high-risk cytogenetics.
Novel Triplet Shows Early Promise for Pretreated CLL
The triplet of umbralisib, ublituximab, and venetoclax induced a complete remission rate of 44% as a treatment for patients with relapsed/refractory chronic lymphocytic leukemia.
Acalabrutinib Triplet Highly Active in Frontline CLL
The triplet of acalabrutinib (Calquence), venetoclax (Venclexta), and obinutuzumab (Gazyva; AVO) is highly active as frontline therapy for patients with chronic lymphocytic leukemia.
Ibrutinib/Rituximab Combo Retains PFS Advantage Over FCR in CLL
With extended follow-up, progression-free survival continues to be superior with the combination of ibrutinib and rituximab compared with fludarabine, cyclophosphamide, and rituximab for patients ≤70 years with previously untreated chronic lymphocytic leukemia.  
Frontline Ibrutinib/Venetoclax Combo Leads to High Rates of Undetectable MRD in CLL
The first-line combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) led to a 75% undetectable minimal residual disease rate in peripheral blood and 72% in bone marrow in patients with chronic lymphocytic leukemia.
Acalabrutinib Alone or in Combination Improves PFS in Frontline CLL
Acalabrutinib (Calquence) as a single agent or in combination with obinutuzumab (Gazyva) significantly improved progression-free survival compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia.
New BTK Agents and Combinations Are on the Horizon for B-cell Malignancies
During a recent OncLive Peer Exchange, a panel of leukemia and lymphoma experts discussed emerging BTK inhibitors. 
Jonathon B. Cohen, MD, MS, discusses the integration of novel agents into clinical practice and the changing role of chemoimmunotherapy in chronic lymphocytic leukemia.
FDA Approves Acalabrutinib for CLL
The FDA has approved acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Publication Bottom Border
Border Publication